Next Phase Newsletter

A single family office based in the US actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries. 
 
The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more. 
 
The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2021 and located in Europe is currently investing out of their first fund and looks to invest in early-stage life science companies in the therapeutics space. The firm focuses on Seed investments in the form of equity. Typical allocation is up to $5M for the first ticket. The firm invests in European companies. 
 
The firm is interested in therapeutics, with a focus on oncology, immunology, rare diseases, fibrotic diseases and CNS. The firm will invest in pre-clinical therapeutic companies. 
 
The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm prefers to lead investments and seeks board seat representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A US-based venture fund invests only in seed and pre-seed rounds, and focuses solely on opportunities in healthcare IT, medtech and consumer health. The firm primarily invests in U.S. based companies but can invest in any geography. 
 
The firm invests in very early stage companies across the healthcare innovation ecosystem, including healthcare IT, medical devices, and consumer health. The firm is highly interested in preventative healthcare, future of work and healthcare IT applications. The firm is open to investing in any area of medicine, but has specific interest in opportunities in cardiology, pulmonary diseases, diabetes, and women’s health. 
 
The firm does not invest in companies that have already raised over $5 million in dilutive capital. The firm seeks to invest in high quality management teams, and prefers to work with experienced entrepreneurs that have a proven track record in their sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A global pharmaceutical firm specialized in the dermatology sector engages in partnerships with early stage companies; these relationships may take a variety of forms, but in most cases the firm forms a partnership around an asset and does not act as a minority equity investor. The firm partners with dermatology startups all around the globe. 
 
The firm is interested in therapeutic programs in the dermatology space, including in acne, dermatology-oncology, and rare diseases of the skin.  The firm will consider partnerships at any stage of development but will only make early stage partnerships if the asset’s risk profile is reasonable. 
 
There are no specific requirements for company and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture arm of a hospital system started investing in early-stage companies through their venture team that was founded in 2022. The team focuses primarily in digital health companies seeking Pre-Seed to Series A investment rounds. The team’s mandate is solving clinical or operational challenges through strategic partnerships that align directly with the hospital system’s core values. The firm does not lead capital investments but will integrate strategic partners into the hospital system through pilot programs before eventually investing in equity. The firm’s equity investments are typically between USD $500k – $2M, but the fund can invest more. The fund is looking to invest in 4-6 companies yearly. 
 
The firm invests primarily within digital health companies that are ready to be integrated within the hospital system; the fund is opportunistic to indication and platform within their digital health investments. The firm may also make investments into diagnostics or medical device companies. For medical device investments, the fund prefers to invest in companies that are nearing clinical completion, or already on market. The fund does not invest in therapeutics. 
 
The fund does not have any strict company or management team requirements. Although an experienced management team is preferred, the fund is willing to invest in any company that is willing to provide tag-along rights. The fund invests within North America, Europe, Australia, and South America and is open to global opportunities that are capable of being integrated into the hospital system. The fund does not typically lead investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with multiple offices throughout US and outside of US invests in several areas of technology including biotech, medical devices and digital health. The firm participates in venture and growth investments as well as buyouts – allocations can range from $5-200m. The firm is open to global opportunities.  
 
Within the healthcare sector, the firm is highly interested in healthcare IT and also has some interest in medical devices and diagnostics. For devices and diagnostics, the firm has a strong preference for investing in products that have already achieved FDA clearance; only exceptional pre-clearance products will be considered and in those cases, the firm will only look at 510k products that are very close to approval; PMAs will not be considered. The firm is open to all indication areas, and has experience and expertise in diabetes, ENT, metabolic diseases, and the spine; the firm generally does not invest in highly invasive medical devices. The firm may also consider opportunities in laboratory tools and analytical drug discovery tools (but not drug discovery service models). In recent, the firm has expanded their investment areas into biotech and life sciences, and is open to investing across all modalities and indications in both pre-clinical and clinical stage assets. 
 
The firm invests in privately-held companies, and prefers to back experienced management teams with previous entrepreneurial successes. The firm prefers to invest in companies with over $2 million in revenue (over $3 million for healthcare IT companies), and with a customer base that includes large hospital networks or high-profile customers. Defensible IP is also a highly important factor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An investor group based in the US is an investing ecosystem that includes Accredited Angel Investors, Healthcare Systems, and Corporate Venture Investors.  The firm focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance. 
 
The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials. 
 
While a management team must be in place, The firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.